Search results for "Tatin"

showing 10 items of 700 documents

Growth hormone replacement therapy prevents sarcopenia by a dual mechanism: improvement of protein balance and of antioxidant defenses.

2013

The aim of our study was to elucidate the role of growth hormone (GH) replacement therapy in three of the main mechanisms involved in sarcopenia: alterations in mitochondrial biogenesis, increase in oxidative stress, and alterations in protein balance. We used young and old Wistar rats that received either placebo or low doses of GH to reach normal insulin-like growth factor-1 values observed in the young group. We found an increase in lean body mass and plasma and hepatic insulin-like growth factor-1 levels in the old animals treated with GH. We also found a lowering of age-associated oxidative damage and an induction of antioxidant enzymes in the skeletal muscle of the treated animals. GH…

Malemedicine.medical_specialtyAgingSarcopeniaIGF-1. Mitochondrial biogenesis Myostatin p70S6KHormone Replacement TherapyMyostatinProtein degradationmedicine.disease_causeAntioxidantsInternal medicineMedicineAnimalsRats WistarMuscle Skeletalbiologybusiness.industryProtein turnoverSkeletal muscleProteinsmedicine.diseaseMitochondria MuscleRatsSomatropinEndocrinologymedicine.anatomical_structureMitochondrial biogenesisSarcopeniaGrowth Hormonebiology.proteinBody CompositionGeriatrics and GerontologybusinessOxidative stressThe journals of gerontology. Series A, Biological sciences and medical sciences
researchProduct

Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: Pleiotropic evidence from plasma mRNA analyses

2013

Objective: Statin pleiotropy is still an evolving concept, and the lack of clarity on this subject is due at least in part to the lack of a definitive biomarker for statin pleiotropy. Using plasma mRNA analysis as a novel research tool for the non-invasive in vivo assessment of gene expression in vascular beds, we hypothesised that atorvastatin lowers the plasmamRNA level from statin pleiotropy-target genes, and the reduction is independent of the reduction of low-density lipoprotein cholesterol (LDL-C). Design and methods: Forty-four patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). Plasma chemokine (C-C motif) ligand 2 (CCL2) and intercellular adhesion molec…

Malemedicine.medical_specialtyChemokineStatinmedicine.drug_classAtorvastatinClinical BiochemistryGene ExpressionDrug Administration ScheduleIn vivoInternal medicineGene expressionAtorvastatinmedicineHumansPyrrolesAngina StableRNA MessengerSerum amyloid AChemokine CCL2AgedbiologyAnticholesteremic AgentsAtorvastatin CCL2 ICAM1 Interventional trial mRNA in plasma Pleiotropic effectsC-reactive proteinCholesterol LDLGeneral MedicineMiddle AgedIntercellular Adhesion Molecule-1EndocrinologyHeptanoic AcidsHMG-CoA reductasebiology.proteinFemalelipids (amino acids peptides and proteins)medicine.drugClinical Biochemistry
researchProduct

Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalitie…

2013

BACKGROUND: Therapeutic intervention with low-density lipoprotein cholesterol-lowering agents known as statins has been demonstrated to reduce cardiovascular risk. However, many patients on statin treatment have persistent dyslipidemia and remain at a high risk of cardiovascular disease. Therefore, the objective of this study was to assess the frequency of lipid abnormalities in patients receiving chronic statin treatment. METHODS: As part of an international, cross-sectional, observational study, DYSIS-Middle East enrolled 2,182 patients in the United Arab Emirates (UAE), Saudi Arabia, Lebanon and Jordan. All patients were over 45 years of age and had been on statin treatment for at least …

Malemedicine.medical_specialtyCross-sectional studylcsh:MedicineComorbidityDiseaseMiddle Eastchemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusPrevalencemedicineHumanscardiovascular diseaseslcsh:ScienceAgedDyslipidemiasMultidisciplinaryCholesterolbusiness.industrylcsh:Rnutritional and metabolic diseasesMiddle AgedStatin treatmentmedicine.diseaseLipidsComorbidityCross-Sectional StudieschemistryPhysical therapyFemalelcsh:Qlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemiaResearch ArticleLipoproteinPLoS ONE
researchProduct

Altered expression of neuropeptides in the primary somatosensory cortex of the Down syndrome model Ts65Dn.

2011

Down syndrome is the most common genetic disorder associated with mental retardation. Subjects and mice models for Down syndrome (such as Ts65Dn) show defects in the formation of neuronal networks in both the hippocampus and the cerebral cortex. The principal neurons display alterations in the morphology, density and distribution of dendritic spines in the cortex as well as in the hippocampus. Several evidences point to the possibility that the atrophy observed in principal neurons could be mediated by changes in their inhibitory inputs and, in fact, an imbalance between excitation and inhibition has been observed in Ts65Dn mice in these regions, which are crucial for learning and informati…

Malemedicine.medical_specialtyDendritic spineHippocampusBiologySomatosensory systemCalbindinHippocampusCellular and Molecular NeuroscienceMiceEndocrinologyInterneuronsCortex (anatomy)Internal medicinemedicineAnimalsNeuronsEndocrine and Autonomic SystemsCalcium-Binding ProteinsNeuropeptidesGeneral MedicineSomatosensory CortexDisease Models Animalmedicine.anatomical_structureEndocrinologySomatostatinnervous systemNeurologyCerebral cortexCalretininDown SyndromeSomatostatinNeuroscienceNeuropeptides
researchProduct

The rs1466113 Polymorphism in the Somatostatin Receptor 2 Gene Is Associated with Obesity and Food Intake in a Mediterranean Population

2009

<i>Background:</i> A genome-wide association study identified rs1466113 (G>C) in the somatostatin receptor 2 (SSTR2) gene as one of the polymorphisms most significantly associated with body mass index (BMI). As replication is required, we examined the association between this polymorphism and anthropometric variables and food intake in a Mediterranean population. <i>Methods:</i> We studied 945 high cardiovascular-risk subjects (340 men and 605 women) aged 67 ± 6 years, participating in the PREDIMED-Valencia Study. Demographic, clinical, biochemical, dietary, genetic and anthropometric data were obtained. <i>Results:</i> We found recessive effects for t…

Malemedicine.medical_specialtyGenotypePopulationMedicine (miscellaneous)BiologyNutrigeneticsBody Mass IndexEatingNutrigenomicsInternal medicineGenotypemedicineHumansSomatostatin receptor 2ObesityReceptors SomatostatineducationGeneAllelesAgededucation.field_of_studyPolymorphism GeneticNutrition and DieteticsMediterranean RegionBody WeightMiddle Agedmedicine.diseaseObesityDietCross-Sectional StudiesLogistic ModelsEndocrinologySomatostatinFemaleBody mass indexAnnals of Nutrition and Metabolism
researchProduct

Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients.

2015

In vitro and animal studies indicate that statins increase heme oxygenase-1 gene (HMOX1) expression, which then, presumably, increases plasma bilirubin concentration. However, clinical confirmation that statins concomitantly increase HMOX1 expression and plasma bilirubin concentration is lacking. We hypothesized that in patients with stable angina atorvastatin therapy (20 mg/day for 10 weeks) concomitantly increases total bilirubin concentration and HMOX1 expression, as assessed non-invasively by plasma analysis.In 44 patients with stable angina plasma concentrations of total bilirubin, HMOX1 mRNA and HMOX1 protein were measured before and after the statin treatment, as well as plasma conce…

Malemedicine.medical_specialtyHMOX1BilirubinAtorvastatinClinical BiochemistryGene Expression Regulation Enzymologicchemistry.chemical_compoundInternal medicinemedicineAtorvastatinHumanscardiovascular diseasesAngina StableRNA MessengerIncreased total bilirubinHemeBilirubinGeneral MedicineMiddle AgedMalondialdehydeEndocrinologychemistryProteolysislipids (amino acids peptides and proteins)FemaleAnimal studiesHeme Oxygenase-1Lipoproteinmedicine.drugScandinavian journal of clinical and laboratory investigation
researchProduct

Effects of cerivastatin on adrenergic pathways, hypertrophic growth and TGFbeta expression in adult ventricular cardiomyocytes.

2010

Abstract The effects of statin treatment in the setting of heart failure have already been shown. Nevertheless, there is little knowledge about its influence on adrenergic pathways in cardiomyocytes. Therefore, this study investigated the impact of cerivastatin on adrenoceptor-mediated signalling pathways in isolated adult ventricular cardiomyocytes. It focused on two endpoints: hypertrophic growth and TGFbeta expression. Cultured cardiomyocytes were used to study rac activation (analysed by its translocation into the membrane fraction), ROS formation (H 2 DCF fluorescence) and hypertrophic growth ( 14 C-phenylalanine incorporation). Alpha- and beta-adrenoceptor stimulation showed significa…

Malemedicine.medical_specialtyHistologyAdrenergic receptorMAP Kinase Signaling SystemPyridinesp38 mitogen-activated protein kinasesHeart VentriclesAdrenergicAlpha (ethology)StimulationPharmacologyp38 Mitogen-Activated Protein KinasesPathology and Forensic MedicineTransforming Growth Factor betaInternal medicineReceptors Adrenergic betamedicineAnimalsMyocytes CardiacRats WistarCells CulturedHeart FailurebiologyCerivastatinCell BiologyGeneral MedicineReceptors Adrenergic alphaRatsEnzyme ActivationEndocrinologyGene Expression RegulationNAD(P)H oxidaseMitogen-activated protein kinasebiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsReactive Oxygen SpeciesProto-Oncogene Proteins c-aktmedicine.drugEuropean journal of cell biology
researchProduct

Altered REDD1, myostatin, and Akt/mTOR/FoxO/MAPK signaling in streptozotocin-induced diabetic muscle atrophy

2011

Type 1 diabetes, if poorly controlled, leads to skeletal muscle atrophy, decreasing the quality of life. We aimed to search highly responsive genes in diabetic muscle atrophy in a common diabetes model and to further characterize associated signaling pathways. Mice were killed 1, 3, or 5 wk after streptozotocin or control. Gene expression of calf muscles was analyzed using microarray and protein signaling with Western blotting. We identified translational repressor protein REDD1 (regulated in development and DNA damage responses) that increased seven- to eightfold and was associated with muscle atrophy in diabetes. The diabetes-induced increase in REDD1 was confirmed at the protein level. …

Malemedicine.medical_specialtyMAP Kinase Signaling SystemPhysiologyEndocrinology Diabetes and MetabolismFOXO1P70-S6 Kinase 1MyostatinBiologyMiceRandom Allocation03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicinemedicineAnimalsRNA MessengerPhosphorylationMuscle SkeletalProtein kinase BPI3K/AKT/mTOR pathwayOligonucleotide Array Sequence Analysis030304 developmental biology0303 health sciencesForkhead Box Protein O1Gene Expression ProfilingTOR Serine-Threonine KinasesUbiquitinationForkhead Transcription FactorsOrgan SizeMyostatinProtein ubiquitinationMuscle atrophyMuscular AtrophyDNA Repair EnzymesDiabetes Mellitus Type 1EndocrinologyGene Expression Regulationbiology.proteinPhosphorylationmedicine.symptomProto-Oncogene Proteins c-akt030217 neurology & neurosurgeryTranscription FactorsAmerican Journal of Physiology-Endocrinology and Metabolism
researchProduct

Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus

2007

Abstract Objective HMG-CoA reductase inhibitors have been shown to upregulate GTP cyclohydrolase I (GTPCH-I), the key enzyme for tetrahydrobiopterin de novo synthesis and to normalize tetrahydrobiopterin levels in hyperglycemic endothelial cells. We sought to determine whether in vivo treatment with the HMG-CoA reductase inhibitor atorvastatin is able to upregulate the GTPCH-I, to recouple eNOS and to normalize endothelial dysfunction in an experimental model of diabetes mellitus. Methods and results In male Wistar rats, diabetes was induced by streptozotocin (STZ, 60mg/kg). In STZ rats, atorvastatin feeding (20mg/kg/d, 7 weeks), normalized vascular dysfunction as analyzed by isometric tens…

Malemedicine.medical_specialtyNitric Oxide Synthase Type IIIGTP cyclohydrolase INitric Oxide Synthase Type IIReductaseArticleDiabetes Mellitus ExperimentalCytochrome P-450 Enzyme SystemEnosInternal medicineAtorvastatinmedicineAnimalsNADH NADPH OxidoreductasesPyrrolesRats WistarEndothelial dysfunctionGTP CyclohydrolaseNADPH oxidasebiologyStem CellsBody WeightMicrofilament ProteinsTetrahydrobiopterinPhosphoproteinsmedicine.diseasebiology.organism_classificationBiopterinRatsEnzyme ActivationIntramolecular OxidoreductasesVasodilationNitric oxide synthaseDisease Models AnimalOxidative StressTetrahydrofolate DehydrogenaseDiabetes Mellitus Type 1EndocrinologyHeptanoic AcidsHMG-CoA reductaseNADPH Oxidase 1biology.proteinEndothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicineCell Adhesion MoleculesDiabetic Angiopathiesmedicine.drugAtherosclerosis
researchProduct

Topical treatment of oral lichen planus with anthocyanins

2014

Background: Oxidative stress is involved in oral lichen planus (OLP) pathogenesis; meanwhile anthocyanins are natural antioxidants present in grapes skin. Objectives: The aim of this research was to verify the utility of anthocyanins, extracted from grapes skin, for the local treatment of oral lichen planus and to compare it with clobetasol propionate- neomycin -nystatin cream (CP-NN). Study Design: Prospective, non-randomized study, with control group. Fifty-two patients with OLP were includ - ed. We divided patients into two categories: erosive oral lichen planus (EOLP) and non erosive oral lichen planus (NEOLP). 38 had EOLP (17 cases and 21 controls) and 14 presented NEOLP types (9 cases…

Malemedicine.medical_specialtyNystatinAdministration TopicalTopical treatmentOdontologíamedicine.disease_causeAnthocyaninsstomatognathic systemmedicineHumansProspective StudiesOral mucosaProspective cohort studyGeneral DentistryClobetasolOral Medicine and Pathologybusiness.industryResearchSignificant differencefungifood and beveragesNeomycinMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludSurgeryDrug Combinationsstomatognathic diseasesmedicine.anatomical_structureNystatinOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryOral lichen planusFemaleClobetasol propionatebusinessOxidative stressmedicine.drugLichen Planus Oral
researchProduct